Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • Everolimus did not demonstrate noninferiority compared with sunitinib as a first-line therapy. The trial results support the standard treatment paradigm of first-line sunitinib followed by everolimus at progression.

publication date

  • September 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5569681

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.54.6911

PubMed ID

  • 25049330

Additional Document Info

start page

  • 2765

end page

  • 72

volume

  • 32

number

  • 25